Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma

Journal of International Medical Research

Volumn 42, Issue 2, 2014, Pages 292-299

  Wang, Xiao Bo ^a   Lin, Ying Li ^b   Li, Zhi Gang ^c   Ma, Jian Hua ^d   Li, Jian ^a   Ma, Jian Guo ^e  

^a TIANJIN PEOPLE'S HOSPITAL   (China)

^b Xuzhou Tumour Hospital   (China)

^c The General Hospital of CNPC   (China)

^d Chengde Central Hospital   (China)

^e HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

bladder cancer; PCDH17; promoter methylation; Protocadherin 17

Indexed keywords

BLADDER CANCER; PCDH17; PROMOTER METHYLATION; PROTOCADHERIN 17;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84898686484     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513504364     Document Type: Article

References (26)

1. Siegel R,Naishadham D,Jemal A.Cancer statistics, 2013.CA Cancer J Clin. 2013;63:11-30.
2. Ploeg M,Aben KK,Kiemeney LA.The present and future burden of urinary bladder cancer in the world.World J Urol. 2009;27:289-293.
3. Gakis G,Kruck S,Stenzl A.Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers?.Curr Opin Urol. 2010;20:388-392.
4. Yegin Z,Gunes S,Buyukalpelli R.Hypermethylation of TWIST1 and NID2 in tumor tissues and voided urine in urinary bladder cancer patients.DNA Cell Biol. 2013;32:386-392.
5. Han H,Wolff EM,Liang G.Epigenetic alterations in bladder cancer and their potential clinical implications.Adv Urol. 2012;2012:546917-546917.
6. Hoffman AM,Cairns P.Epigenetics of kidney cancer and bladder cancer.Epigenomics. 2011;3:19-34.
7. Hu X,Sui X,Li L, et al.Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.J Pathol. 2013;229:62-73.
8. Andrés G,Ashour N,Sánchez-Chapado M, et al.The study of DNA methylation in urological cancer: present and future.Actas Urol Esp. 2013;37:368-375.
9. Theveneau E,Mayor R.Cadherins in collective cell migration of mesenchymal cells.Curr Opin Cell Biol. 2012;24:677-684.
10. Lin YL,Li ZG,He ZK, et al.Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer.J Int Med Res. 2012;40:2117-2123.
11. Kim SY,Yasuda S,Tanaka H, et al.Non-clustered protocadherin.Cell Adh Migr. 2011;5:97-105.
12. Yang Y,Liu J,Li X, et al.PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer.Histol Histopathol. 2012;27:217-224.
13. Costa VL,Henrique R,Danielsen SA, et al.TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.Epigenetics. 2011;6:1120-1130.
14. Oosterlinck W,Lobel B,Jakse G, et al.Guidelines on bladder cancer.Eur Urol. 2002;41:105-112.
15. Lin YL,Ma JH,Luo XL, et al.Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer.J Int Med Res. 2013;41:48-54.
16. Lee YC,Wu WJ,Li WM, et al.Prognostic value of p53 protein overexpression in upper tract urothelial carcinomas in Taiwan.Anticancer Res. 2013;33:1091-1098.
17. Yan JA,Xiao H,Ji HX, et al.Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder.J Int Med Res. 2010;38:1913-1922.
18. Morgan TM,Clark PE.Bladder cancer.Curr Opin Oncol. 2010;22:242-249.
19. García-Baquero R,Puerta P,Beltran M, et al.Methylation of a novel panel of tumor suppressor genes in urine moves forward noninvasive diagnosis and prognosis of bladder cancer: a 2-center prospective study.J Urol. 2013;190:723-730.
20. Delpu Y,Cordelier P,Cho WC, et al.DNA methylation and cancer diagnosis.Int J Mol Sci. 2013;14:15029-15058.
21. Kandimalla R,van Tilborg AA,Zwarthoff EC.DNA methylation-based biomarkers in bladder cancer.Nat Rev Urol. 2013;10:327-335.
22. Haruki S,Imoto I,Kozaki K, et al.Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma.Carcinogenesis. 2010;31:1027-1036.
23. Herr HW,Dotan Z,Donat SM, et al.Defining optimal therapy for muscle invasive bladder cancer.J Urol. 2007;177:437-443.
24. Shariat SF,Karakiewicz PI,Palapattu GS, et al.Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.J Urol. 2006;176 (Pt 1): 2414-2422.
25. van Rhijn BW,Burger M,Lotan Y, et al.Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.Eur Urol. 2009;56:430-442.
26. Lin YL,Sun G,Liu XQ, et al.Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.J Int Med Res. 2011;39:179-186.